Table 1.
Demographic and clinical details of postmortem midbrain mRNA cohort
| mRNA cohort | |||
|---|---|---|---|
| Demographic | Control mRNA (n = 29) | Schizophrenia mRNA (n = 28) | Statistics mRNA |
| Age (years) | 51.2 (22–69) | 51.4 (26–67) | p = 0.90, df = 55, t = −0.06 |
| Gender (M, F) | (20,9) | (19,9) | – |
| pH | 6.67 ± 0.26 | 6.51 ± 0.20* | p = 0.01, df = 55, t = 2.6 |
| PMI h | 31.9 ± 10.12 (15–50) | 35.7 ± 17.71 (5–72) | p = 0.33, df = 55, t = −0.98 |
| RIN | 5.6 ± 1.14 | 5.6 ± 1.31 | p = 0.95, df = 55, t = −0.06 |
| Duration of illness (years) | na | 28.31 ± 12.72 (4–49) [28, 19–39] | – |
| Daily chlorpromazine equivalent dose (mg) | na | 736.45 ± 520.50 (n = 22) [583.0, 387.5–825.0] | – |
| Last recorded chlorpromazine equivalent dose (mg) | na | 597.54 ± 497.64 (n = 28) [462.5, 192.5–927.0] | – |
| Lifetime chlorpromazine equivalent dose (g) | na | 8231.44 ± 8714.24 (n = 22) [4726.8, 3442.0–8563.0] | – |
| Depression symptoms over lifetime (yes, no, unknown) | 1 (SSRI), 26, 2 | 8 (6 on SSRIs, 2 on TCAs), 19, 1 | – |
| Symptoms (mostly positive, mostly negative, unknown) | na | 18, 7, 3 | – |
| Agonal state (rapid/intermediate/prolonged/unknown) | 18/10/0/1 | 17/9/0/2 | – |
| Manner of death$ (illness, trauma, natural causes/suicide) | 29/0 | 21/7 | |
| Smoker at time of death (yes/no/unknown) | 11/12/6 | 16/6/6 | – |
F female, M male, RIN RNA integrity, PMI postmortem interval, na not applicable, SSRIs serotonin reuptake inhibitors, TCAs tricyclic antidepressants
Data are mean ± SD (range) (median, interquartile range). $See Supplementary Material for further information. *p < 0.05